Evidence map›Paper›PMID 30950086›Full record

ArticleBritish journal of clinical pharmacology2019

Drugs for the treatment of metabolic bone diseases.

Matthew T Drake, Serge Cremers, R Graham Russell, John P Bilezikian

Open access · bronzeAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Drugs for the treatment of metabolic bone diseases.British journal of clinical pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Matthew T DrakeDepartment of Endocrinology and Kogod Center of Aging, Mayo Clinic College of Medicine, Rochester, Minnesota.ORCID 0000-0002-3662-7345
Serge CremersDivision of Laboratory Medicine, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York City, New York.ORCID 0000-0002-6800-5532
R Graham RussellMellanby Centre for Bone Research, Medical School, University of Sheffield, Sheffield, UK.ORCID 0000-0002-4136-1828
John P BilezikianDivision of Endocrinology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York City, New York.ORCID 0000-0002-1570-2617
Columbia University Irving Medical Center · USMayo Clinic · USNuffield Orthopaedic Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBone Density Conservation AgentsBone DiseasesBone RemodelingFemaleHumansMaleOsteoporosisOsteoporotic FracturesRisk AssessmentRisk FactorsTreatment OutcomeBone Density Conservation Agents

Identifiers

PMID30950086
PMCPMC6533457
OpenAlexW2934363406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.